Cutaneous leishmaniasis otherwise Healthy. minor skin disease
Conditions
Interventions
Intervention 1: Treatment with topical Nano liposomal form of 10% paromomycin, twice a day for 28 days. Intervention 2: Placebo topically is used twice a day for 28 days.
Treatment - Drugs
Placebo
Treatment with topical Nano liposomal form of 10% paromomycin, twice a day for 28 days
Placebo topically is used twice a day for 28 days
Sponsors
Center for Research & Training in Skin Diseases & Leprosy Tehran University of Medical Sciences; Dis
Eligibility
Sex/Gender
All
Age
12 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria:Age 12-60 years; Cutaneous leishmaniasis (CL) lesion induced by L. major; Parasitological proven cases of CL by direct smear, culture or PCR; Healthy individual otherwise of CL; onset less than 3 months; number of lesion 5 at most; ulcer size not more than 30 mm in one size; willing to participate and sign informed consent. Exclusion criteria: pregnant or lactating women; duration of lesion more than 3 months; serious illness such as heart kidney or liver diseases based on physical exam and laboratory tests; CL lesion resistant to treatment or recidivans form of lesion; number of lesions more than 5; ulcer size more than 30 mm in one direction participation in any other clinical trial in last 6 months.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete cure. Timepoint: at weeks 4 and 8 and at months 3 and 6. Method of measurement: Measurement of reepithelization. | — |
Secondary
| Measure | Time frame |
|---|---|
| Partial cure. Timepoint: at weeks 4 and 8 and at months 3 and 6. Method of measurement: Measurement of reepithelization. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Ali Khamesipour
Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences
Outcome results
None listed